Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Peripherally inserted central catheter

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    16 result(s) found for: Peripherally inserted central catheter. Displaying page 1 of 1.
    EudraCT Number: 2005-003194-24 Sponsor Protocol Number: CPI-226-03 Start Date*: 2006-01-02
    Sponsor Name:Cadence Pharmaceuticals, Inc.
    Full Title: Estudio en fase III, multicéntrico, aleatorizado, con enmascaramiento del tratamiento para el comité de evaluación para valorar la eficacia de la administración tópica de omiganán al 1,0% en gel en...
    Medical condition: Prevención de infecciones en la zona del catéter. Prevention of local site infections in patients requiring central venous and/or arterial catheterization and/or peripherally inserted central veno...
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002124-32 Sponsor Protocol Number: CUSA-081-HEM-01 Start Date*: 2020-01-02
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: READY 1: A Phase 3, Randomized, Double-Blind, Active and Placebo-Controlled Study on the use of CUSA-081 for Dysfunctional Central Venous Access Devices (CVADs)
    Medical condition: Catheter Occlusion Thrombosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) ES (Prematurely Ended) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2011-003938-14 Sponsor Protocol Number: MK-5592-069(P06200) Start Date*: 2013-04-09
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3 Randomized Study of the Efficacy and Safety of Posaconazole versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults and Adolescents (Phase 3; Protocol No. MK-5592-069)
    Medical condition: Invasive aspergillosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10003488 Aspergillosis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) BE (Completed) LT (Prematurely Ended) PT (Completed) GB (Completed) EE (Completed) IT (Completed) PL (Completed) GR (Completed) FR (Completed) HU (Completed) CZ (Completed) HR (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2016-003517-95 Sponsor Protocol Number: OP-103 Start Date*: 2017-01-31
    Sponsor Name:Oncopeptides AB
    Full Title: A Randomized, Controlled, Open-Label, Phase 3 Study of Melflufen/ Dexamethasone Compared with Pomalidomide/Dexamethasone for Patients with Relapsed Refractory Multiple Myeloma who are Refractory to...
    Medical condition: Patients with Relapsed Refractory Multiple Myeloma who are Refractory to Lenalidomide
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004851 10028229 Multiple myelomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Ongoing) CZ (Completed) GB (GB - no longer in EU/EEA) GR (Temporarily Halted) BE (Completed) DK (Completed) NL (Completed) NO (Completed) FR (Completed) PL (Completed) AT (Completed) EE (Completed) LT (Completed) IT (Completed) RO (Temporarily Halted)
    Trial results: View results
    EudraCT Number: 2021-004026-30 Sponsor Protocol Number: CUSA-081-HEM-02 Start Date*: 2022-02-14
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: READY 2: A PHASE 3, OPEN LABEL, SINGLE ARM STUDY ON THE USE OF CUSA-081 FOR DYSFUNCTIONAL CENTRAL VENOUS ACCESS DEVICES (CVADs)
    Medical condition: Catheter Occlusion Thrombosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002161-36 Sponsor Protocol Number: OP-108 Start Date*: Information not available in EudraCT
    Sponsor Name:Oncopeptides AB
    Full Title: A Randomized, Controlled, Open-Label Phase 3 Study of Melflufen in combination with Daratumumab Compared with Daratumumab in Patients with Relapsed or Relapsed-Refractory Multiple Myeloma
    Medical condition: Patients with relapsed or relapsed-refractory multiple myeloma.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004851 10028229 Multiple myelomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) NO (Completed) HU (Completed) FI (Completed) SK (Prematurely Ended) BG (Prematurely Ended) PL (Prematurely Ended) GR (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004127-21 Sponsor Protocol Number: OP-109 Start Date*: 2020-04-16
    Sponsor Name:Oncopeptides AB
    Full Title: A randomized, two-period, cross-over, Phase 2 study, comparing the pharmacokinetics, and assessing safety and tolerability of peripheral and central intravenous administration of melflufen in patie...
    Medical condition: Patients with relapsed and refractory multiple myeloma.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004851 10028229 Multiple myelomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BG (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2023-001028-40 Sponsor Protocol Number: RIV-PN-201 Start Date*: 2024-01-15
    Sponsor Name:United Therapeutics Corp
    Full Title: Intravenous Remodulin (Treprostinil) as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn: A Randomized, Placebo-Controlled, Safety and Efficacy Study
    Medical condition: Persistant Pulmonary Hypertension of the Newborn (PPHN)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    Population Age: Preterm newborn infants, Newborns, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-002807-10 Sponsor Protocol Number: 5592-097 Start Date*: 2015-09-02
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous (IV) and Powder for Oral Suspension Formulations of Posaconazole (POS) in Immunocompromised Pediatric Subjects with Neutropenia
    Medical condition: Prophylaxis of invasive fungal infections in immunocompromised pediatric subjects with neutropenia or expected neutropenia.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10017534 Fungal infection NOS LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) NO (Completed) SE (Completed) DK (Completed) CZ (Completed) ES (Completed) BE (Completed) IT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-002120-24 Sponsor Protocol Number: OP-104 Start Date*: 2017-12-14
    Sponsor Name:Oncopeptides AB
    Full Title: An Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination with either Bortezomib or Daratumumab in Patients with Relapsed or Relapsed-Refractory Multip...
    Medical condition: Patients with Relapsed or Relapsed-Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004851 10028229 Multiple myelomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Prematurely Ended) PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-000478-31 Sponsor Protocol Number: OP-107 Start Date*: 2018-07-09
    Sponsor Name:Oncopeptides AB
    Full Title: A Study of the Pharmacokinetics of Melphalan During Treatment with Melflufen and Dexamethasone in Patients with Relapsed Refractory Multiple Myeloma and Impaired Renal Function
    Medical condition: Patients with Relapsed Refractory Multiple and Impaired Renal Function
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004851 10028229 Multiple myelomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) PL (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002267-10 Sponsor Protocol Number: MK-5592-104 Start Date*: 2019-12-17
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole (POS, MK-5592) in Pediatric Participants Aged 2 to <18 Years With Invasive Aspergillosis
    Medical condition: Invasive aspergillosis (IA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10003488 Aspergillosis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) Outside EU/EEA GR (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004349-35 Sponsor Protocol Number: 7001 Start Date*: 2021-02-02
    Sponsor Name:Klinisk Forskningsenhed, Medicinsk Afdeling, Hæmatologisk Afsnit, Sygehus Lillebælt, Vejle Sygehus
    Full Title: Melphalan flufenamide (melflufen) and Dexamethasone re-induction in Daratumumab-refractory Multiple Myeloma as an Adjunct to Continued Daratumumab (MERMAID)
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000820-20 Sponsor Protocol Number: NVG111-101 Start Date*: 2020-10-30
    Sponsor Name:NovalGen Ltd
    Full Title: AN OPEN-LABEL, PHASE 1/2, FIRST IN HUMAN STUDY INVESTIGATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF NVG-111 IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA ...
    Medical condition: RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA AND MANTLE CELL LYMPHOMA
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008976 Chronic lymphocytic leukemia LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026801 Mantle cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-003842-34 Sponsor Protocol Number: MK-5592-127 Start Date*: Information not available in EudraCT
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 2, Open-Label, Single-Arm, Sequential-Panel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Posaconazole (POS, MK-5592) Intravenous and Powder for Oral Suspension Formul...
    Medical condition: Invasive Fungal Infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10017533 Fungal infection PT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: PL (Trial now transitioned) Outside EU/EEA BE (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-000528-39 Sponsor Protocol Number: TAK-676-1002 Start Date*: 2023-03-20
    Sponsor Name:Takeda Development Center Americas, Inc. (TDC Americas)
    Full Title: An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Ad...
    Medical condition: Solid Neoplasms
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 09:47:37 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA